-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen ...

Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely ...

Caldwell, Idaho – 26 January, 2016 –Regarded as the leader in steel target innovation and manufacturing for over 20 years, MGM Targets saw a need for development of a versatile, durable and economical ...

The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Leerink Partners on November 17, 2025. The analyst firm set a price target for $2.00 expecting IPSC to rise to within 12 ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** I enjoy punching paper targets ...

Shares of Century Therapeutics, Inc. (IPSC) have gained 9.7% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term ...

Investing.com - Leerink Partners has lowered its price target on Fate Therapeutics (NASDAQ:FATE) to $7.00 from $12.00 while maintaining an Outperform rating on the stock. The new target still ...

A team of scientists from the New York Stem Cell Foundation (NYSCF) Research Institute and Case Western Reserve University has created the largest reported collection of stem cell models from multiple ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price cut by HC Wainwright from $5.00 to $2.00 in a research report report published on Thursday morning,Benzinga reports. They ...